Gilead Sciences names new chief scientific officer and chief medical officer

Gilead Sciences has announced a series of leadership changes after confirming the departure of Dr Norbert Bischofberger as executive vice-president for research and development and chief scientific officer.

Dr Bischofberger will vacate the role at the end of April, having joined Gilead in 1990. Over nearly 30 years with the company, he has overseen the development of more than 25 compounds for treating serious medical conditions.

Dr John Milligan, Gilead's president and chief executive officer, said: "There are few people across the entire biopharmaceutical industry who have had the kind of impact Norbert has had on transforming the treatment of serious diseases."

Succeeding him will be Dr John McHutchison, who currently serves as executive vice-president for clinical research at Gilead. He will assume responsibility for the company's research and development organisation, working alongside Dr Bischofberger, who will remain with the company until July to aid the transition process.

Meanwhile, Dr Andrew Cheng is being promoted from head of clinical research and development operations to the post of chief medical officer, taking on responsibility for medical affairs.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.